◆ American Journal of Hematology2026-01-08· Medicine
Post‐ <scp>FDA</scp> Approval Experience With Momelotinib in <scp>JAK</scp> Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy
Ayalew Tefferi, Maymona Abdelmagid, Jeanne Palmer, Aref Al‐Kali, Cecilia Y. Arana Yi, Aasiya Matin, Hassan B. Alkhateeb, Talha Badar, Yassin Bashir, Kaaren K. Reichard, Rong He, Animesh Pardanani, Naseema Gangat
原始摘要（英文原文）· Original abstract
Real-world experience using momelotinib as first-line JAK2 inhibitor therapy in myelofibrosis. Anemia response was moderate (23%) while treatment-emergent adverse events included nephropathy (29%) and peripheral neuropathy (20%).
Post‐ <scp>FDA</scp> Approval Experience With Momelotinib in <scp>JAK</scp> Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy — 科研速览 Science Skim